Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters

Shuofeng Yuan(University of Hong Kong), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Vincent Kwok‐Man Poon(Queen Mary Hospital), Naoko Matsunaga(Sanford Burnham Prebys Medical Discovery Institute), Chun‐Kit Yuen(University of Hong Kong), Chris Chun-Yiu Chan(University of Hong Kong), Xiangzhi Meng(University of Hong Kong), Kelvin Kai‐Wang To(Hong Kong Science and Technology Parks Corporation), Ren Sun(University of California, Los Angeles), Kaiming Tang(University of Hong Kong), Lars Pache(Sanford Burnham Prebys Medical Discovery Institute), Dong‐Yan Jin(University of Hong Kong), Hin Chu(HKU-Pasteur Research Pole), Jasper Fuk‐Woo Chan(Hong Kong Baptist University), Kong‐Hung Sze(University of Hong Kong), Jianli Cao(University of Hong Kong), Jinxia Zhang(Peking University), Ronghui Liang(University of Hong Kong), Sumit K. Chanda(Sanford Burnham Prebys Medical Discovery Institute), Pok-Man Lai(University of Hong Kong), Zi‐Wei Ye(Harbin University of Science and Technology), Yuan Pu(The Ohio State University), Sheng Li(University of California, Los Angeles), Xin Yin(Sanford Burnham Prebys Medical Discovery Institute), Kin‐Hang Kok(University of Hong Kong), Yushen Du(University of California, Los Angeles), Wan Xu(University of Hong Kong), Laura Riva(Scripps Research Institute)
Research Square
October 7, 2020
Cited by 22


Related Papers